WO2024097916A3 - Compositions and methods for treating a condition associated with keratin 17 aberrant expression - Google Patents
Compositions and methods for treating a condition associated with keratin 17 aberrant expression Download PDFInfo
- Publication number
- WO2024097916A3 WO2024097916A3 PCT/US2023/078574 US2023078574W WO2024097916A3 WO 2024097916 A3 WO2024097916 A3 WO 2024097916A3 US 2023078574 W US2023078574 W US 2023078574W WO 2024097916 A3 WO2024097916 A3 WO 2024097916A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- aberrant expression
- methods
- treating
- keratin
- Prior art date
Links
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 title abstract 3
- 230000001594 aberrant effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108010066325 Keratin-17 Proteins 0.000 title 1
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure provides compositions (e.g., pharmaceutical compositions) and methods for treating conditions associated with aberrant expression of KRT17, including psoriasis and certain malignancies. The compositions comprise antisense oligonucleotides that reduce aberrant expression of KRT17.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263422076P | 2022-11-03 | 2022-11-03 | |
US63/422,076 | 2022-11-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024097916A2 WO2024097916A2 (en) | 2024-05-10 |
WO2024097916A3 true WO2024097916A3 (en) | 2024-07-11 |
Family
ID=90931654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/078574 WO2024097916A2 (en) | 2022-11-03 | 2023-11-03 | Compositions and methods for treating a condition associated with keratin 17 aberrant expression |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024097916A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063563A2 (en) * | 2006-11-16 | 2008-05-29 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mtor inhibitors |
-
2023
- 2023-11-03 WO PCT/US2023/078574 patent/WO2024097916A2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063563A2 (en) * | 2006-11-16 | 2008-05-29 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mtor inhibitors |
Non-Patent Citations (1)
Title |
---|
CHANG ET AL.: "Inhibition of keratin 17 expression with antisense and RNAi strategies: exploring novel therapy for psoriasis", EXPERIMENTAL DERMATOLOGY, vol. 20, 2011, XP071776830, [retrieved on 20240409], DOI: https://onlinelibrary. wiley .com/doi/10.1111/ j.1600-0625.2010.01235.x * |
Also Published As
Publication number | Publication date |
---|---|
WO2024097916A2 (en) | 2024-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011550A (en) | Compositions and methods for inhibiting angptl3 expression. | |
WO2022031847A3 (en) | Compositions and methods for inhibiting plp1 expression | |
CA3188924A1 (en) | Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain | |
MX2023001538A (en) | COMPOSITIONS AND METHODS FOR INHIBITING <i>LPA</i> EXPRESSION. | |
BR0314514A (en) | Modafinil Pharmaceutical Formulations | |
WO2022218941A3 (en) | Compositions and methods for inhibiting ketohexokinase (khk) | |
MXPA04006039A (en) | Methods for the treatment of peripheral neural and vascular ailments. | |
AU3451797A (en) | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter | |
MX2023001997A (en) | Bicyclic compounds, compositions and use thereof. | |
AU1416795A (en) | Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament | |
MX2021013901A (en) | Compositions and methods for treating cancer. | |
PA8599701A1 (en) | DOSAGE FORMS AND TREATMENT PROCEDURES USING VEGFR INHIBITORS | |
CR20220570A (en) | Compositions comprising nanoparticles, method of making and uses thereof | |
WO2004076445A3 (en) | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | |
MX2022000733A (en) | Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. | |
MX2024005107A (en) | Novel use of quinazolinone compound for the treatment of cancer. | |
MX2023010711A (en) | Phenalkylamines and methods of making and using the same. | |
MX2024001417A (en) | Heteroaryl compounds for treating huntington's disease. | |
MX2024001590A (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders. | |
BRPI0414822A (en) | method of inhibiting the production of remaining lipoprotein | |
WO2024097916A3 (en) | Compositions and methods for treating a condition associated with keratin 17 aberrant expression | |
MX2022012404A (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases. | |
MX2023013504A (en) | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression. | |
PL370361A1 (en) | Alkyl urea retinoid agonists i | |
WO2023091644A3 (en) | Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23887036 Country of ref document: EP Kind code of ref document: A2 |